Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Previous Page Next Page

Clinical Data

The efficacy and safety of entrectinib has been studied in phase 1/2 clinical trials (ALKA-372-001, STARTRK-1 and -2, and STARTRK-NG) in adult and paediatric patients, with or without identified NTRK, ROS1 or ALK gene fusions [1-3].

Click on the following links to learn more about the currently available efficacy and safety outcomes from these trials.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.